Segall Bryant & Hamill LLC Raises Stock Holdings in Insulet Corporation (NASDAQ:PODD)

Segall Bryant & Hamill LLC raised its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 25.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 90,332 shares of the medical instruments supplier's stock after acquiring an additional 18,567 shares during the quarter. Segall Bryant & Hamill LLC owned 0.13% of Insulet worth $23,722,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Independent Advisor Alliance grew its holdings in Insulet by 20.8% during the fourth quarter. Independent Advisor Alliance now owns 1,378 shares of the medical instruments supplier's stock valued at $360,000 after purchasing an additional 237 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Insulet by 2.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock valued at $566,000 after acquiring an additional 50 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Insulet by 3.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 16,665 shares of the medical instruments supplier's stock valued at $4,351,000 after buying an additional 508 shares during the last quarter. Frank Rimerman Advisors LLC bought a new position in shares of Insulet in the fourth quarter valued at about $220,000. Finally, Natixis Advisors LLC increased its position in Insulet by 33.8% in the fourth quarter. Natixis Advisors LLC now owns 44,371 shares of the medical instruments supplier's stock worth $11,584,000 after purchasing an additional 11,210 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Citigroup reiterated a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Oppenheimer lifted their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $321.00.

Insulet Price Performance

Shares of Insulet stock traded up $1.90 during mid-day trading on Friday, reaching $285.35. 110,549 shares of the stock were exchanged, compared to its average volume of 716,331. The company has a market cap of $20.08 billion, a price-to-earnings ratio of 51.32, a price-to-earnings-growth ratio of 2.57 and a beta of 1.35. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The firm has a 50-day simple moving average of $309.59 and a 200 day simple moving average of $280.69. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. Insulet's quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 EPS. On average, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.39% of the stock is currently owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.